Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.83 |
| ▸ | ARG2 | P78540 | 4/20 | 0.52 |
| ▸ | ARG1 | P05089 | 3/20 | 0.52 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | NOS3 | P29474 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.45 |
| ▸ | GRM6 | O15303 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL17102268 | 1.00 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL8562830 | 0.92 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL22534312 | 0.92 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL2324976 | 0.92 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL3359527 | 0.91 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL12867528 | 0.91 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL456381 | 0.91 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL9439278 | 0.91 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL7343 | 0.91 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL1000151 | 0.91 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025051692-A1 | DETOXIFYING PEPTIDE | REGENTIS PHARMA (FR) | 2025-03-13 | — | — | WO | disclosed |
| CN-119064480-A | Screening method of UPLC-MS-based drug for inhibiting activity of advanced glycosylation end product | 南京理工大学 | 2024-12-03 | — | — | CN | disclosed |
| US-11391727-B2 | Methods for improving cardiovascular disease management | JOURNEY BIOSCIENCES INC. (US) | 2022-07-19 | — | — | US | disclosed |
| CN-114624362-A | Kit for detecting advanced glycosylation end products in serum and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2022-06-14 | — | — | CN | disclosed |
| US-20210333268-A1 | METHODS FOR IMPROVING CARDIOVASCULAR DISEASE MANAGEMENT | JOURNEY BIOSCIENCES INC. | 2021-10-28 | — | — | US | disclosed |
| US-20190328710-A1 | SYNERGISTIC COMPOSITION FOR INHIBITING ADVANCED GLYCATION END PRODUCT CROSSLINKING | H2 WATER TECHNOLOGIES LTD. (CA) | 2019-10-31 | — | — | US | disclosed |
| US-10363339-B2 | Water absorbent agent composition and method for producing same, as well as storage and stocking method for same | NIPPON SHOKUBAI CO., LTD. (JP) | 2019-07-30 | — | — | US | disclosed |
| US-20180340926-A1 | METHODS FOR IMPROVING DIABETES MANAGEMENT | JOURNEY BIOSCIENCES, LLC | 2018-11-29 | — | — | US | disclosed |
| US-20180306747-A1 | METHODS FOR IMPROVING DIABETES MANAGEMENT | PREVENAGE HEALTHCARE LLC (US) | 2018-10-25 | — | — | US | disclosed |
| EP-2706360-B1 | Method and kit for improving diabetes management by determining methylglyoxal hydroimidazolone (MGH1) | PREVENTAGE HEALTHCARE LLC (US) | 2018-10-03 | — | — | EP | disclosed |
| US-20140299815-A1 | WATER ABSORBENT AGENT COMPOSITION AND METHOD FOR PRODUCING SAME, AS WELL AS STORAGE AND STOCKING METHOD FOR SAME | NIPPON SHOKUBAI CO., LTD. (JP) | 2014-10-09 | — | — | US | disclosed |
| EP-2781259-A1 | WATER ABSORBENT COMPOSITION AND METHOD FOR PRODUCING SAME, AS WELL AS STORAGE AND STOCKING METHOD FOR SAME | Nippon Shokubai Co., Ltd. (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-8809329-B2 | Detection and treatment of schizophrenia | TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) | 2014-08-19 | — | — | US | disclosed |
| EP-2706360-A1 | Methods for improving diabetes management | PreventAge Healthcare, LLC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20130345175-A1 | Methods for Improving Diabetes Management | PREVENTAGE HEALTHCARE, LLC | 2013-12-26 | — | — | US | disclosed |
| EP-2662453-A2 | Detection and treatment of schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2013-11-13 | — | — | EP | disclosed |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2011142460-A1 | METHOD FOR DETECTING SCHIZOPHRENIA | 財団法人東京都医学総合研究所 (JP) | 2011-11-17 | — | — | WO | disclosed |
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2189537-A1 | DETECTION AND TREATMENT OF SCHIZOPHRENIA | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2010-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | GSR 27/4885ARG2 2112/4885ARG1 3797/4885 |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | GSR 27/4885ARG2 2112/4885ARG1 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.